应用2017年修订版国际共识指南判断胰腺导管内乳头状黏液性肿瘤的恶性潜能:CT与MRI对比
本研究回顾性分析2007年1月至2017年12月手术切除的86例胰腺导管内乳头状黏液性肿瘤(IPMN)患者,评估2017年修订版国际共识指南预测恶性潜能的效能,并比较增强CT与MRI的诊断表现和一致性。结果显示强化壁结节≥5 mm与恶性IPMN关联最强,CT与MRI诊断效能相当且一致性良好。
要点
- 强化壁结节≥5 mm与恶性IPMN关联最强,CT的OR为25,MRI的OR为29。
- 主胰管突然变细、淋巴结肿大、主胰管径较大、囊液生长速率较快在恶性IPMN中更常见。
- 增强CT与MRI预测恶性IPMN的AUC分别为0.83和0.86,两者相当(P=0.43),一致性良好(κ=0.70)。
核心结论
- 在修订版指南的各项特征中,强化壁结节≥5 mm与恶性IPMN关联最强;增强CT与MRI预测恶性IPMN的诊断效能相当,且两者间一致性良好。
研究设计与样本
- 回顾性研究,纳入2007年1月至2017年12月手术切除的胰腺IPMN患者86例(平均年龄67.6岁±8.9岁,男47例、女39例;良性58例、恶性28例),由两名放射科医师分析术前增强CT和MRI,采用受试者工作特征曲线分析诊断效能,采用加权κ和组内相关系数评估检查间一致性。
关键影像表现/征象
- 强化壁结节在恶性IPMN中较良性更常见(P<.001)。
- 主胰管管径突然改变在恶性IPMN中较良性更常见(P<.001)。
- 淋巴结肿大在恶性IPMN中较良性更常见(P=.006)。
- 主胰管径较大在恶性IPMN中较良性更常见(P=.003)。
- 囊液生长速率较快在恶性IPMN中较良性更常见(P=.04)。
诊断标准与关键数值
- 强化壁结节≥5 mm的比值比最高,CT为25,MRI为29。
- CT预测恶性IPMN的AUC为0.83(95%CI:0.75,0.92)。
- MRI预测恶性IPMN的AUC为0.86(95%CI:0.77,0.95)。
- CT与MRI诊断效能比较P=.43,检查间一致性κ=0.70。
临床应用与阅片要点
- 阅片时应重点评估强化壁结节大小,≥5 mm对提示恶性IPMN价值最高。
- 报告中应描述主胰管管径及是否突然改变、淋巴结肿大、囊液生长速率等修订版指南特征。
- 增强CT与MRI均可用于预测恶性IPMN,两者诊断效能相当且一致性良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Several changes have been made to the revised 2017 international consensus guidelines for management of pancreatic intraductal papillary mucinous neoplasms (IPMNs). However, the diagnostic performance is yet to be verified. Purpose To evaluate the revised guidelines for predicting malignant potential of pancreatic IPMNs and to compare diagnostic performance and intermodality agreement between contrast material-enhanced CT and MRI. Materials and Methods In this retrospective study, two radiologists analyzed the preoperative contrast-enhanced CT and MRI of patients with surgically resected pancreatic IPMNs from January 2007 to December 2017. The diagnostic performance of CT and MRI were analyzed by using receiver operating curve analysis. Intermodality agreement was assessed by using weighted κ and intraclass correlation coefficient values. Results A total of 86 patients (mean age, 67.6 years ± 8.9 [standard deviation]; 47 men and 39 women) with pancreatic IPMNs (benign, 58; malignant, 28) were included. At both CT and MRI, enhancing mural nodule (P < .001), abrupt main pancreatic duct caliber change (P < .001), lymphadenopathy (P = .006), larger main pancreatic duct size (P = .003), and faster cyst growth rate (P = .04) were more common in malignant than benign IPMNs. Irrespective of the modality, enhancing mural nodule of 5 mm or greater had the highest odds ratio (25 at CT vs 29 at MRI). The diagnostic performance of CT (area under the receiver operating characteristic curve, 0.83 [95% confidence interval: 0.75, 0.92]) and MRI (area under the receiver operating characteristic curve, 0.86 [95% confidence interval: 0.77, 0.95]) for predicting malignant IPMNs were comparable (P = .43), with good intermodality agreement (κ = 0.70). Conclusion Among revised features, enhancing mural nodule of 5 mm or greater had the strongest association with malignant intraductal papillary mucinous neoplasm (IPMN), and diagnostic performance for prediction of malignant IPMNs were comparable between contrast-enhanced CT and MRI with good intermodality agreement. © RSNA, 2019 Online supplemental material is available for this article.
引用
- Lee JE, Choi SY, Min JH, et al. Determining Malignant Potential of Intraductal Papillary Mucinous Neoplasm of the Pancreas: CT versus MRI by Using Revised 2017 International Consensus Guidelines. Radiology. 2019. PMID: 31478800. doi:10.1148/radiol.2019190144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。